147 related articles for article (PubMed ID: 30597357)
1. Update on the pathology of liver neoplasms.
Matsukuma KE; Yeh MM
Ann Diagn Pathol; 2019 Feb; 38():126-137. PubMed ID: 30597357
[TBL] [Abstract][Full Text] [Related]
2. [Pathology of liver tumors].
Schirmacher P
Internist (Berl); 2020 Feb; 61(2):131-139. PubMed ID: 31953548
[TBL] [Abstract][Full Text] [Related]
3. Pathology of combined hepatocellular-cholangiocarcinoma.
Yeh MM
J Gastroenterol Hepatol; 2010 Sep; 25(9):1485-92. PubMed ID: 20796144
[TBL] [Abstract][Full Text] [Related]
4. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract][Full Text] [Related]
5. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
6. Histopathology of a benign bile duct lesion in the liver: Morphologic mimicker or precursor of intrahepatic cholangiocarcinoma.
Lee KB
Clin Mol Hepatol; 2016 Sep; 22(3):400-405. PubMed ID: 27729636
[TBL] [Abstract][Full Text] [Related]
7. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
[TBL] [Abstract][Full Text] [Related]
8. Cytologic features of fibrolamellar carcinoma with mucin production: a rare variant of combined hepatocellular-cholangiocarcinoma.
Rosa M; Mohammadi A
Diagn Cytopathol; 2014 May; 42(5):431-5. PubMed ID: 23008149
[TBL] [Abstract][Full Text] [Related]
9. Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.
Sasaki M; Matsubara T; Kakuda Y; Sato Y; Nakanuma Y
Am J Surg Pathol; 2014 Mar; 38(3):364-9. PubMed ID: 24487593
[TBL] [Abstract][Full Text] [Related]
10. Hepatic adenoma and focal nodular hyperplasia.
Shortell CK; Schwartz SI
Surg Gynecol Obstet; 1991 Nov; 173(5):426-31. PubMed ID: 1658955
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study.
Washington K; Telen MJ; Gottfried MR
Liver; 1997 Feb; 17(1):17-23. PubMed ID: 9062875
[TBL] [Abstract][Full Text] [Related]
12. Imaging approach to hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer.
Fowler KJ; Saad NE; Linehan D
Surg Oncol Clin N Am; 2015 Jan; 24(1):19-40. PubMed ID: 25444467
[TBL] [Abstract][Full Text] [Related]
13. Sarcomatoid combined hepatocellular-cholangiocarcinoma: a case report and review of literature.
Chin S; Kim Z
Int J Clin Exp Pathol; 2014; 7(11):8290-4. PubMed ID: 25550887
[TBL] [Abstract][Full Text] [Related]
14. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
[TBL] [Abstract][Full Text] [Related]
15. [Tumor grading of the hepatobiliary system].
Jütte H; Tannapfel A
Pathologe; 2016 Jul; 37(4):299-303. PubMed ID: 27342594
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings.
Zhao YJ; Chen WX; Wu DS; Zhang WY; Zheng LR
Abdom Radiol (NY); 2016 May; 41(5):978-89. PubMed ID: 27193795
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
[TBL] [Abstract][Full Text] [Related]
18. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
[TBL] [Abstract][Full Text] [Related]
19. Synchronous hepatocellular carcinoma and cholangiocarcinoma arising in two different dysplastic nodules.
Kwon Y; Lee SK; Kim JS; Ro JY; Yu E
Mod Pathol; 2002 Oct; 15(10):1096-101. PubMed ID: 12379757
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular cancer, cholangiocarcinoma, and metastatic tumors of the liver.
Wagman LD
Surg Oncol Clin N Am; 2015 Jan; 24(1):xiii-xiv. PubMed ID: 25444478
[No Abstract] [Full Text] [Related]
[Next] [New Search]
